Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 4,29€ (+227,48%). La mediana es de 4,29€ (+227,48%).
| Comprar |
2 |
| Mantener |
0 |
| Vender |
0 |
Noticias Ir al feed de noticias
Insider purchase at OKYO Pharma: CSO Raj Patil increases holdings
Raj Patil, chief scientific officer of OKYO Pharma, bought 3,363 common shares on the NASDAQ at $1.49 each, bringing his holdings to 20,030 shares. OKYO Pharma is preparing to start a global phase‑3 trial in the second half of the year with about 111 patients to evaluate a single dose of urcosimod for neuropathic corneal pain. » Más en de.investing.com
OKYO Pharma: CEO Robert J. Dempsey buys 15,000 shares at $1.54
Chief Executive Officer Robert J. Dempsey purchased 15,000 common shares of OKYO Pharma on the open market at $1.54 per share on the NASDAQ. OKYO Pharma is listed on the Nasdaq Capital Market and plans to start a global phase‑3 single‑dose study of urcosimod for neuropathic corneal pain in the second half of the year with about 111 patients. The company is in the clinical development phase for anterior segment eye therapies. » Más en de.investing.com
OKYO Pharma: chief development officer Gary S. Jacob buys 3,500 shares
Gary S. Jacob, chief development officer and director of OKYO Pharma, purchased 3,500 common shares at $1.40 each on the Nasdaq, bringing his total holding to 112,420 shares. OKYO Pharma’s common stock is listed on the Nasdaq Capital Market. The biopharmaceutical company plans to start a global, registration‑enabling Phase 3 study of urcosimod for the treatment of neuropathic corneal pain in the second half of the year, likely with around 111 patients and a single‑dose regimen. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | mar 2026 | |
|---|---|---|
| Ingresos | 0,00 | - |
| Beneficio bruto | −807,75 | - |
| Beneficio neto | −5,50M | - |
| EBITDA | −5,53M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 51,07M€ |
Número de acciones | 38,37M |
Máximo/mínimo de 52 semanas | 2,75€ - 1,15€ |
| Dividendos | No |
Beta | 0,05 |
Ratio P/E | −6,48 |
Ratio PEG | 0,05 |
Ratio P/B | 4,70 |
Ratio P/S | 0,00 |
Perfil de la empresa
OKYO Pharma Limited, ein präklinisches biopharmazeutisches Unternehmen, entwickelt im Vereinigten Königreich Therapeutika für Patienten, die an entzündlichen Augenerkrankungen und Augenschmerzen leiden. Zu seinem führenden Produkt gehört OK-101 zur Behandlung von Erkrankungen des trockenen Auges. Das Unternehmen entwickelt außerdem OK-201, einen präklinischen Kandidaten für ein lipidiertes Peptidanalogon aus Rindernebennierenmark zur Behandlung von neuropathischen Augenschmerzen. OKYO Pharma Limited wurde im Jahr 2007 gegründet und hat seinen Hauptsitz in London, Vereinigtes Königreich.
| Nombre | OKYO PHARMA LTD Aktie |
| CEO | Robert J. Dempsey |
| Sede | London,
gl Reino Unido |
| Sitio web | |
| Industria | Productos alimenticios |
| Salida a bolsa | 17/05/2022 |
| Empleados | 5 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | OKYO |
Frankfurt | OK11.F |
München | OK11.MU |
Descubrir activos
Los accionistas de OKYO PHARMA LTD Aktie también invierten en los siguientes activos
